reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccarelli et al.
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
M E
ME
Lacouture
D002289:Carcinoma, Non-Small-Cell Lung; D006801:Humans; D008175:Lung Neoplasms; D019936:Probiotics; D052999:Quinazolinones
D052999:Quinazolinones; C525726:dacomitinib
Ann Oncol. 2016 Sep;27(9):1712-8
27287210